Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Oncologic Outcome After Radical Prostatectomy In Men With PSA Values Above 20 ng/ml: A Monocentric Experience

K. N. Nguyen, Stephanie Eltz, S. Drouin, E. Compérat, F. Audenet, R. Renard-Penna, M. Bitker, E. Chartier-Kastler, F. Richard, O. Cussenot, M. Rouprêt
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
ObjectiveTo assess the cancer control afforded by radical prostatectomy (RP) in patients with prostate-specific antigen (PSA) values above 20 ng/ml.MethodsWe performed a retrospective review of prostate cancer patients who had initial PSA values above 20 ng/ml and were treated with surgery between 1995 and 2006. Biochemical recurrence was defined as a single rise in PSA levels over 0.2 ng/ml after surgery.ResultsOverall, 41 patients were included. The mean age was 62 ± 6.43 years. The mean PSA was 27.39 ± 13.57 ng/ml (range 20.3–80). After pathological analysis, prostate cancer was organ-confined in 21 cases (51.2%) and locally advanced in 20 cases (48.8%). Positive surgical margins were detected in 36.5% of cases (n = 15). Five patients had lymph node involvement (12%). The mean prostate volume was 58 ± 28.9 cc. The mean length of follow-up after surgery was 94 ± 37 months. Median time to biochemical recurrence was 44.6 ± 22 months. The 5-year PSA-free survival rate was 53%. Through univariate analysis, the pathologic stage (p = 0.016), biopsy and pathological Gleason scores (p = 0.013; p = 0.02) and positive margin (p = 0.04) were associated with recurrence. Overall, 24 patients (58.5%) experienced a biochemical recurrence. Only margin status and pathological Gleason were significant in multivariate analysis (p < 0.05).ConclusionRP can be recommended as a viable primary treatment option in selected cases of the high-risk cohort of patients with pre-operative PSA values above 20 ng/ml. However, the modalities of adjuvant treatments following RP remain to be defined in patients who are likely to evolve unfavourably.
This paper references
10.1016/J.PUROL.2008.03.016
« Big PSA» et prostatectomie totale : survie spécifique et globale à dix ans
A. Paul (2008)
10.1093/JNCI/DJJ190
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
A. Stephenson (2006)
10.1007/BF02914519
Should patients with a pre-operative prostatespecific antigen greater than 15ng/ml be offered radical prostatectomy?
M. O’Brien (2004)
10.1016/J.EURURO.2006.12.010
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL.
A. Gallina (2007)
10.1016/J.UROLOGY.2003.09.029
Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer.
C. Diblasio (2003)
10.1038/sj.pcan.4500892
The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml
C. Bastide (2006)
10.1016/S0022-5347(01)69079-7
Cancer control with radical prostatectomy alone in 1,000 consecutive patients.
Gerald W Hull (2002)
10.1016/J.EURURO.2007.03.056
Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy.
U. Zwergel (2007)
10.3322/CA.2007.0010
Cancer Statistics, 2008
A. Jemal (2008)
10.1046/j.1464-410X.2003.04269.x
Biochemical disease‐free survival in patients with a high prostate‐specific antigen level (20–100 ng/mL) and clinically localized prostate cancer after radical prostatectomy
D. W. Brandli (2003)
10.1016/J.JURO.2006.08.007
Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
A. Villers (2006)
10.1046/j.1464-410X.2003.t01-4-04488.x
Biochemical disease‐free survival in patients with a high prostate‐specific antigen level (20–100 ng/mL) and clinically localized prostate cancer after radical prostatectomy
E. Neulander (2003)
10.1200/JCO.2004.01.164
Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease.
A. D'Amico (2004)
10.1097/01.JU.0000173907.84852.EC
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.
S. Freedland (2005)
10.1016/j.juro.2007.11.061
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
S. Boorjian (2008)
10.1111/j.1464-410X.2008.08208.x
Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single‐centre experience
E. Xylinas (2009)
10.1016/S1078-1439(02)00187-4
The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL.
B. P. Vanasupa (2002)
Combination of prostatespeci W c antigen , clinical stage , and Gleason score to predict pathological stage of localized prostate cancer . A multiinstitutional update
AW Partin (1997)
10.1111/j.1464-410X.2007.07263.x
The effect of prostate weight on the outcomes of laparoscopic radical prostatectomy
R. Frota (2008)
10.1089/END.2004.18.605
Extraperitoneal standard laparoscopic radical prostatectomy.
F. Rozet (2004)
10.1148/RADIOL.2451061502
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results.
B. Bloch (2007)
10.1056/NEJMoa074311
Quality of life and satisfaction with outcome among prostate-cancer survivors.
M. Sanda (2008)
10.1016/j.purol.2008.03.016
[High PSA and total prostatectomy: specific and overall 10-year survival].
A. Paul (2008)
10.1001/JAMA.1997.03540420041027
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
A. Partin (1997)
10.1056/NEJMoa1011967
Radical prostatectomy versus watchful waiting in early prostate cancer.
A. Bill‐Axelson (2011)



This paper is referenced by
10.3389/fonc.2019.01286
Significance of Time Until PSA Recurrence After Radical Prostatectomy Without Neo- or Adjuvant Treatment to Clinical Progression and Cancer-Related Death in High-Risk Prostate Cancer Patients
Ž. Venclovas (2019)
10.1007/s00345-013-1089-0
Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL
C. Dariane (2013)
10.1016/j.eururo.2012.02.031
High-risk prostate cancer: from definition to contemporary management.
P. Bastian (2012)
10.1016/J.ACURO.2018.02.007
Resultados oncológicos a largo plazo del tratamiento cáncer de próstata de alto riesgo mediante prostatectomía radical en un hospital oncológico
J. Rubio-Briones (2018)
Radical prostatectomy outcome when performed with PSA above 20 ng/ml.
S. S. Connolly (2011)
10.1016/J.ACUROE.2018.07.003
Long-term oncological results of treatment for high-risk prostate cancer using radical prostatectomy in a cancer hospital
José Rubio-Briones (2018)
10.1007/s10354-015-0389-y
The role for surgeryin high-risk prostate cancer
C. Lanchon (2015)
10.1111/j.1442-2042.2012.03068.x
Feasibility of minimally invasive radical prostatectomy in prostate cancer patients with high prostate‐specific antigen: Feasibility and 1‐year outcomes
M. Do (2012)
10.1155/2012/832974
Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA  >20 ng/mL
A. Hinev (2012)
10.1586/era.10.36
Contemporary treatment of high-risk localized prostate cancer
B. Tareen (2010)
10.1016/j.purol.2018.08.007
Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature.
G. Delporte (2018)
10.1038/ki.2013.459
Biphasic recruitment of microchimeric fetal mesenchymal cells in fibrosis following acute kidney injury.
E. Roy (2014)
10.1007/s00345-010-0608-5
Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study
A. Masson-Lecomte (2010)
10.1016/J.ACURO.2010.03.029
Progresión metastática, mortalidad cáncer específica y necesidad de tratamientos de segunda línea en pacientes con cáncer de próstata de alto riesgo tratados inicialmente mediante prostatectomía radical
J. Rubio-Briones (2010)
10.1016/S2173-5786(10)70149-9
[Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy].
J. Rubio-Briones (2010)
10.1016/j.urolonc.2009.11.023
Nerve-sparing robotic prostatectomy in preoperatively high-risk patients is safe and efficacious.
H. Lavery (2012)
Semantic Scholar Logo Some data provided by SemanticScholar